STK11 and non-small cell lung carcinoma: Through the synergistic implementation of NSCLC patient-derived airway organoids, we additionally elucidate the molecular mechanism through which the tumour suppressor LKB1 may orchestrate metabolic adaptation in LUAD, offering a unique opportunity for meaningful therapeutic interventions.